The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
True or False: In a phase 1b/2 trial evaluating the efficacy and safety of venetoclax plus CPX-531 for the treatment of R/R acute myeloid leukemia, the combination therapy showed promising clinical activity, especially among patients in...
Rami Komrokji, MD; Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO
This discussion between experts addresses unmet needs in the acute myeloid leukemia treatment landscape (AML) and the efficacy and safety of a treatment option for patients with relapsed and refractory AML with isocitrate dehydrogenase 1...
This discussion between experts addresses unmet needs in the acute myeloid leukemia treatment landscape (AML) and the efficacy and safety of a treatment option for patients with relapsed and refractory AML with isocitrate dehydrogenase 1...
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
The FDA issued a safety alert regarding tazemetostat, citing an increased risk of hematologic second primary malignancies observed in the ongoing SYMPHONY-1 trial.
The FDA issued a safety alert regarding tazemetostat, citing an increased risk of hematologic second primary malignancies observed in the ongoing SYMPHONY-1 trial.
Based on results from the BGB-11417-201 trial, the FDA has approved sonrotoclax for previously treated patients with relapsed/refractory mantle cell lymphoma.
Based on results from the BGB-11417-201 trial, the FDA has approved sonrotoclax for previously treated patients with relapsed/refractory mantle cell lymphoma.
The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
The FDA granted approval to the first fully oral regimen of decitabine and cedazuridine plus venetoclax for adults with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...
